Business, energy, technology, markets and global industry news from Business News Today

oral SERD

PharmaDeviceNews oral SERD
Representative image of an oncology consultation, illustrating how Roche and Genentech’s giredestrant FDA priority review could reshape endocrine therapy decisions in early-stage breast cancer.
Pharma & Biotech

Roche’s giredestrant FDA review raises the stakes in adjuvant breast cancer treatment

Find out how Roche’s giredestrant FDA priority review could reshape endocrine therapy in early breast cancer.

Read More
Representative image showing a modern breast cancer consultation as Menarini’s elacestrant and capivasertib data raise fresh questions about oral targeted therapy in metastatic disease.
Pharma & Biotech

Menarini’s ASCO 2026 ELEVATE data raise bigger question on oral oncology combinations

Menarini’s elacestrant strategy is shifting from monotherapy to combinations. Can ELEVATE data support a broader breast cancer role?

Read More
Pharma & Biotech

Can Eli Lilly’s Inluriyo outpace rivals in ESR1-mutated breast cancer after EMBER-3?

Eli Lilly and Company has released updated Phase 3 EMBER-3 results for Inluriyo, also known as imlunestrant, its oral estrogen receptor antagonist, in patients with estrogen receptor-positive and human epidermal growth factor receptor 2–negative advanced or metastatic breast cancer. These new data, presented at the 2025 San Antonio Breast Cancer Symposium and published in Annals

Read More